NDUFAF3 Gene

Migration, Crosslink

📖

NDUFAF3 Gene

active

wiki page Created: 2026-04-02T07:19:22 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-ndufaf3

📖 Wiki Page

gene3956 wordssynced 2026-04-02

NDUFAF3 — NADH Dehydrogenase Complex Assembly Factor 3

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">NADH Dehydrogenase Complex Assembly Factor 3</th></tr>
<tr><td>Gene Symbol</td><td>NDUFAF3</td></tr>
<tr><td>Full Name</td><td>NADH Dehydrogenase Complex Assembly Factor 3</td></tr>
<tr><td>Alternative Names</td><td>C3orf60, MRPS18</td></tr>
<tr><td>Chromosome</td><td>3p21.31</td></tr>
<tr><td>NCBI Gene ID</td><td>[55244](https://www.ncbi.nlm.nih.gov/gene/55244)</td></tr>
<tr><td>OMIM</td><td>618196</td></tr>
<tr><td>Ensembl ID</td><td>ENSG00000163293</td></tr>
<tr><td>UniProt ID</td><td>[Q9P0U4](https://www.uniprot.org/uniprot/Q9P0U4)</td></tr>
<tr><td>Protein Length</td><td>198 amino acids</td></tr>
<tr><td>Molecular Weight</td><td>~22 kDa</td></tr>
<tr><td>Subcellular Location</td><td>Mitochondria (mitochondrial matrix)</td></tr>
<tr><td>Expression</td><td>High in brain, heart, muscle (high energy tissues)</td></tr>
<tr><td>Associated Diseases</td><td>[Leigh Syndrome](/diseases/leigh-syndrome), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), Complex I Deficiency</td></tr>
</table>
</div>

Overview

...

NDUFAF3 — NADH Dehydrogenase Complex Assembly Factor 3

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">NADH Dehydrogenase Complex Assembly Factor 3</th></tr>
<tr><td>Gene Symbol</td><td>NDUFAF3</td></tr>
<tr><td>Full Name</td><td>NADH Dehydrogenase Complex Assembly Factor 3</td></tr>
<tr><td>Alternative Names</td><td>C3orf60, MRPS18</td></tr>
<tr><td>Chromosome</td><td>3p21.31</td></tr>
<tr><td>NCBI Gene ID</td><td>[55244](https://www.ncbi.nlm.nih.gov/gene/55244)</td></tr>
<tr><td>OMIM</td><td>618196</td></tr>
<tr><td>Ensembl ID</td><td>ENSG00000163293</td></tr>
<tr><td>UniProt ID</td><td>[Q9P0U4](https://www.uniprot.org/uniprot/Q9P0U4)</td></tr>
<tr><td>Protein Length</td><td>198 amino acids</td></tr>
<tr><td>Molecular Weight</td><td>~22 kDa</td></tr>
<tr><td>Subcellular Location</td><td>Mitochondria (mitochondrial matrix)</td></tr>
<tr><td>Expression</td><td>High in brain, heart, muscle (high energy tissues)</td></tr>
<tr><td>Associated Diseases</td><td>[Leigh Syndrome](/diseases/leigh-syndrome), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/als), Complex I Deficiency</td></tr>
</table>
</div>

Overview

NDUFAF3 (NADH Dehydrogenase Complex Assembly Factor 3) encodes a critical mitochondrial assembly factor required for the proper assembly and function of complex I (NADH:ubiquinone oxidoreductase) of the mitochondrial electron transport chain[@saada2009][@guo2020]. Complex I is the largest and most complex enzyme of the oxidative phosphorylation system, and its assembly requires the coordinated action of over 40 core subunits and numerous assembly factors including NDUFAF3[@guo2020][@str运会2019].

NDUFAF3 functions as part of an early assembly module that includes NDUFAF4 and NDUFAF6, facilitating the initial steps of complex I biogenesis[@calleja2020]. Mutations in NDUFAF3 cause severe mitochondrial complex I deficiency, leading to early-onset encephalopathy and lactic acidosis, often presenting as [Leigh syndrome](/diseases/leigh-syndrome)[@saada2009]. Beyond these rare genetic disorders, impaired complex I function due to NDUFAF3 dysfunction has been increasingly recognized as contributing to more common neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@pfaffl2021][@anderson2018][@mohan2019].

Pathophysiology

Complex I Deficiency Mechanisms

Complex I (NADH:ubiquinone oxidoreductase) is the entry point for electrons into the mitochondrial respiratory chain, catalyzing the oxidation of NADH and the reduction of coenzyme Q. The deficiency of complex I activity in NDUFAF3-related disorders occurs through multiple mechanisms:

Assembly Defects
NDUFAF3 mutations disrupt the early assembly of complex I. The protein normally forms a subcomplex with NDUFAF4 and NDUFAF6, which serves as a nucleation site for the incorporation of core subunits. Without functional NDUFAF3, this early assembly step fails, resulting in incomplete complex formation and rapid degradation of assembly intermediates.

Subunit Incorporation Failure
NDUFAF3 is specifically required for the incorporation of mtDNA-encoded ND1 into the nascent complex. ND1 is a critical subunit that forms part of the ubiquinone-binding pocket. Without proper ND1 incorporation, the entire complex fails to mature properly.

Stability Issues
Mutant NDUFAF3 proteins often have reduced stability, leading to decreased protein levels. This further compounds the assembly defect, as the limiting assembly factor cannot support normal complex I biogenesis rates.

Cellular Consequences

The loss of complex I activity has profound cellular consequences:

ATP Production Deficit
Complex I is a major contributor to the proton gradient that drives ATP synthesis. Reduced complex I activity means less proton pumping, reducing the electrochemical gradient and limiting ATP production through ATP synthase.

NAD+ Depletion
Complex I oxidizes NADH to NAD+. Without functional complex I, NADH cannot be oxidized efficiently, leading to a depletion of the cellular NAD+ pool. NAD+ is essential for numerous metabolic processes including sirtuin activity, DNA repair, and cellular signaling.

Reactive Oxygen Species Generation
Complex I is a significant source of reactive oxygen species (ROS) in mitochondria. Dysfunctional complex I can actually increase ROS production through electron leakage, particularly at sites where assembly is incomplete.

Metabolic Dysregulation
The NAD+/NADH ratio affects numerous metabolic pathways. Impaired complex I function disrupts glycolysis, the TCA cycle, and fatty acid oxidation, creating a cascade of metabolic dysfunction.

Tissue-Specific Vulnerability

Different tissues show varying vulnerability to NDUFAF3 dysfunction:

Brain
Neurons have high energy demands and are particularly dependent on mitochondrial function. Complex I deficiency leads to neuronal death, particularly in regions with high metabolic activity. The characteristic lesions in Leigh syndrome affect the brainstem and basal ganglia.

Heart
Cardiac muscle requires continuous ATP production for contractile function. Complex I deficiency impairs cardiac energetics, leading to cardiomyopathy in some patients.

Skeletal Muscle
Muscle fibers with high oxidative capacity are affected, leading to exercise intolerance and weakness.

Role in Neurodegenerative Diseases

Alzheimer's Disease Pathogenesis

In [Alzheimer's disease](/diseases/alzheimers-disease)[@mohan2019][@ruiz2017][@van2021], complex I dysfunction plays a significant role in disease pathogenesis:

Mitochondrial Cascade Hypothesis
The mitochondrial cascade hypothesis proposes that mitochondrial dysfunction is an early event in AD pathogenesis, potentially preceding amyloid pathology. NDUFAF3 expression changes may contribute to this early mitochondrial deficit.

Amyloid-β Effects
Aβ accumulates within mitochondria in AD brains. Aβ binds to complex I, directly inhibiting its activity. Additionally, Aβ disrupts mitochondrial dynamics, affecting the biogenesis of new complexes.

Tau Pathology
Hyperphosphorylated tau disrupts mitochondrial transport in neurons, preventing proper distribution of mitochondria to synaptic regions. This leads to localized energy deficits at synapses.

Energy Failure
The combination of complex I dysfunction and other mitochondrial deficits leads to severe neuronal energy failure. Synaptic function is particularly affected due to the high energy requirements of synaptic transmission.

Oxidative Stress
Dysfunctional complex I produces increased ROS, contributing to oxidative damage in AD brains. Lipid peroxidation, protein oxidation, and DNA damage are all elevated in AD.

Parkinson's Disease Connections

In [Parkinson's disease](/diseases/parkinsons-disease)[@anderson2018][@schondorf2018], complex I deficiency is particularly prominent:

Substantia Nigra Vulnerability
The dopaminergic neurons of the substantia pars compacta have particularly high mitochondrial requirements. Complex I deficiency in these neurons leads to their selective vulnerability.

PINK1/Parkin Pathway
The PINK1/Parkin pathway regulates mitochondrial quality control. Loss-of-function mutations in PINK1 and PARKIN cause familial PD. This pathway may interact with complex I assembly factors including NDUFAF3.

Environmental Toxins
MPTP and rotenone, which cause Parkinsonism in humans and animal models, specifically inhibit complex I. This demonstrates the critical importance of complex I function for dopaminergic neuron survival.

Alpha-Synuclein Interactions
Mitochondrial dysfunction and complex I deficiency may interact with alpha-synuclein aggregation, creating a feed-forward loop of neurodegeneration.

Amyotrophic Lateral Sclerosis

In [ALS](/diseases/als)[@link2019][@chen2020]:

Motor Neuron Vulnerability
Motor neurons have extremely high energy requirements for maintaining long axons and neuromuscular junctions. Complex I deficiency compromises this energy demand, leading to axonal dysfunction and death.

Mitochondrial Dynamics
ALS-associated proteins (SOD1, TDP-43, FUS) affect mitochondrial dynamics. Combined with complex I dysfunction, this creates severe mitochondrial pathology.

Excitotoxicity
Mitochondrial dysfunction contributes to excitotoxicity through impaired calcium handling and ATP-dependent glutamate transport failure.

With normal aging[@van2021]:

Declining Assembly Capacity
NDUFAF3 expression decreases in aged brain, reducing the capacity for complex I assembly and maintenance.

mtDNA Mutations
Aging is associated with accumulation of mtDNA mutations, many of which affect complex I subunits.

Proteostasis Decline
Aging reduces the capacity to properly fold and maintain proteins, including assembly factors like NDUFAF3.

Protein Structure and Function

NDUFAF3 is a mitochondrial matrix protein that functions as an assembly factor rather than a core structural component of complex I:

N-terminal Region (1-60 aa)

Mitochondrial targeting sequence: N-terminal transit peptide for mitochondrial import
Matrix localization signal: Directs protein to mitochondrial matrix

Central Region (60-140 aa)

Interaction domain: Mediates binding to NDUFAF4 and early complex I subunits
Assembly module interface: Part of the NDUFAF3-NDUFAF4-NDUFAF6 subcomplex

C-terminal Region (140-198 aa)

Assembly function domain: Required for early assembly step catalysis
Stability domain: Maintains protein stability in mitochondrial environment

NDUFAF3 does not become part of the mature complex I but acts transiently during the assembly process, similar to other assembly factors[@lazarou2015][@perdomini2013].

Normal Cellular Function

Mitochondrial Complex I Assembly

Complex I (NADH dehydrogenase) is the first enzyme of the mitochondrial respiratory chain, catalyzing NADH oxidation and electron transfer to ubiquinone[@guo2020][@koopman2016]:

Early assembly module formation: NDUFAF3 assembles with NDUFAF4 and early-accumulating subunits (ND1, ND2, ND3)

Core module construction: The hydrophobic arm of complex I is built progressively

Peripheral arm addition: The catalytic modules are added subsequently

Final maturation: Additional subunits and cofactors are incorporated

Quality control: Assembly intermediates are monitored and defective complexes are degraded

NDUFAF3 specifically facilitates the incorporation of the ND1 subunit and the formation of the Q module of complex I[@str运会2019].

Energy Metabolism

Proper complex I function is essential for cellular energy production:

Oxidative phosphorylation: Complex I transfers electrons from NADH to coenzyme Q
ATP synthesis: Electron transfer drives proton pumping and ATP synthesis
NAD+/NADH balance: Complex I maintains cellular NAD+ levels
Metabolic regulation: Electron transport influences metabolic pathways

Neuronal Function

In neurons, proper complex I function is particularly critical[@calleja2020][@karaman2018]:

High energy demands of synaptic function
Complex I is the primary site of reactive oxygen species (ROS) production
Neuronal survival depends on mitochondrial bioenergetics
Complex I dysfunction leads to synaptic failure

Role in Neurodegenerative Diseases

Leigh Syndrome

NDUFAF3 mutations are a well-established cause of Leigh syndrome[@saada2009][@ibrahim2020]:

Autosomal recessive inheritance
Severe complex I deficiency (typically <30% residual activity)
Presentation in infancy or early childhood
Characteristic brainstem lesions on MRI
Progressive neurodegeneration with lactic acidosis
Most patients present with developmental regression, hypotonia, and respiratory difficulties

Alzheimer's Disease

NDUFAF3 and complex I dysfunction contribute to [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis[@mohan2019][@ruiz2017][@van2021]:

Mitochondrial Dysfunction

AD brains consistently show complex I deficiency:

NDUFAF3 expression is altered in AD brain tissue
Reduced complex I activity in AD mitochondria
Impaired NAD+ regeneration affects neuronal function

Amyloid and Tau Connection

Aβ and tau pathology affect complex I:

Aβ accumulation impairs complex I assembly
Tau pathology disrupts mitochondrial dynamics
NDUFAF3 expression is suppressed by Aβ

Energy Failure

Complex I dysfunction contributes to AD energy crisis:

Reduced ATP production in neurons
Impaired synaptic function and plasticity
Activation of cell death pathways

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease)[@anderson2018][@schondorf2018]:

Complex I Deficiency

PD is strongly associated with complex I dysfunction:

Complex I activity is reduced in PD substantia nigra
NDUFAF3 expression is altered in PD models
Mitochondrial dysfunction is an early event

Neurotoxin Models

Complex I inhibitors replicate PD features:

MPTP and rotenone models act through complex I blockade
These models demonstrate NDUFAF3 involvement
Rescue by complex I enhancement is possible

Genetic Forms

PD-linked genes affect complex I:

PINK1 and Parkin regulate mitochondrial quality control
NDUFAF3 dysfunction may contribute to sporadic PD
Interaction with known PD genes

Amyotrophic Lateral Sclerosis

In [ALS](/diseases/als)[@link2019][@chen2020]:

Complex I deficiency in ALS motor neurons
NDUFAF3 expression is altered in ALS
Mitochondrial dysfunction contributes to motor neuron death
Energy failure is an early event in pathogenesis

Aging and Neurodegeneration

Complex I function declines with aging[@van2021]:

NDUFAF3 expression decreases in aged brain
Accumulated mitochondrial DNA mutations affect complex I
Reduced complex I assembly capacity

Molecular Mechanisms

Complex I Assembly Process

Complex I (NADH:ubiquinone oxidoreductase) is the largest OXPHOS complex, comprising 45 subunits. NDUFAF3 functions as an assembly factor that facilitates the early stages of complex I biogenesis[@guo2020][@str运会2019].

Stage 1: Core Module Formation
NDUFAF3 participates in early Q-module assembly, forming a subcomplex with NDUFAF4 and NDUFAF6 to incorporate the mtDNA-encoded ND1 subunit.

Stage 2: Hydrophobic Arm Assembly
Additional ND subunits are added sequentially as intermediate complexes are formed.

Stage 3: Peripheral Arm Addition
Catalytic modules attach to the membrane arm, establishing the Q-binding site.

Stage 4: Maturation and Quality Control
Assembly factors including NDUFAF3 dissociate from the mature complex, and defective complexes are degraded.

Regulation

Transcriptional: PGC-1α co-activates NDUFAF3 expression, with thyroid hormone and estrogen modulating expression.

Post-translational: Phosphorylation affects activity, acetylation influences stability, and O-GlcNAcylation occurs in metabolic stress.

Environmental: Exercise enhances assembly, caloric restriction improves function, and hypoxia affects complex I.

Clinical Genetics

Inheritance

NDUFAF3-related disorders follow autosomal recessive inheritance. Heterozygous carriers are typically healthy with 25% recurrence risk for affected couples.

Known Variants

Missense: p.Ser155Asn (decreased assembly), p.Arg171Trp (impaired stability), p.Gly198Glu (disrupted interface).

Truncating: p.Tyr76X (complete loss), p.Arg215X (truncated), frameshift mutations.

Splice: c.524+1G>A (exon skipping), c.356-2A>G (intron retention).

Population Genetics

NDUFAF3 mutations are rare with carrier frequency <1:500 and disease prevalence ~1:200,000.

Diagnostic Approaches

Biochemical

Complex I activity in muscle, blue-native PAGE, elevated lactate in blood/CSF, and high-resolution oxygraphy.

Molecular

Targeted gene panels, whole exome/genome sequencing.

Imaging

MRI shows Leigh syndrome lesions, MRS shows elevated lactate peaks.

Therapeutic Strategies

Current Management

Seizure control, CoQ10 (100-300 mg/day), L-carnitine (50-100 mg/kg/day), riboflavin, physical/occupational/speech therapy.

Emerging

Gene therapy (AAV), complex I assembly enhancers, mitochondrial biogenesis inducers, CRISPR gene editing.

Prognosis

Infantile-onset forms have severe prognosis with early mortality. Late-onset forms are more variable with better outcomes possible. Early intervention improves outcomes.

Protein-Protein Interactions

| Protein | Interaction Type | Functional Significance |
|---------|-----------------|------------------------|
| NDUFAF4 | Direct binding | Core assembly subcomplex |
| NDUFAF6 | Direct binding | Assembly module |
| ND1 (MT-ND1) | Direct binding | Early subunit incorporation |
| ND2 (MT-ND2) | Indirect | Module assembly |
| MT-CO1 | Indirect | Assembly coordination |
| HSC20 | Direct binding | Iron-sulfur cluster delivery |
| LYRM7 | Indirect | Complex III coordination |
| COA6 | Indirect | Complex IV coordination |

Therapeutic Implications

Targeting Mitochondrial Function

Approaches to address NDUFAF3-related dysfunction:

Gene therapy: Deliver functional NDUFAF3

Small molecule assembly enhancers: Promote complex I assembly

Cofactor supplementation: Support mitochondrial function

Antioxidants: Combat ROS from dysfunctional complex I

Metabolic modulators: Enhance alternative energy pathways

Challenges

Delivery to neurons is challenging
Timing of intervention is critical
Off-target effects possible
Compensation mechanisms may limit efficacy

Research Directions

Current Questions

How does NDUFAF3 dysfunction specifically affect neurons?
Can complex I assembly be enhanced pharmacologically?
What is the relationship between NDUFAF3 and sporadic neurodegeneration?
Are there neuron-specific therapeutic targets?

Emerging Areas

iPSC models of NDUFAF3 deficiency
Single-cell analysis of complex I assembly
Gene editing approaches for NDUFAF3 mutations
Mitochondria-targeted therapeutics

Clinical Presentation and Diagnosis

Patients with pathogenic NDUFAF3 variants typically present with[@saada2009][@ibrahim2020]:

Onset and Course

Infantile onset: Most patients present within the first year of life
Early childhood: Some patients may present between 1-5 years
Progressive course: Progressive deterioration is typical
Variable severity: Phenotypic spectrum ranges from mild to severe

Neurological Manifestations

Developmental delay: Global developmental delay is common
Hypotonia: Central hypotonia often present at onset
Seizures: Epileptic seizures reported in many cases
Ataxia: Cerebellar ataxia in some patients
Dystonia: Movement disorders including dystonia
Optic atrophy: Visual impairment due to optic nerve involvement
Sensorineural hearing loss: Auditory neuropathy reported

Systemic Manifestations

Lactic acidosis: Elevated lactate in blood and CSF
Cardiomyopathy: Some patients develop cardiac involvement
Hepatomegaly: Liver enlargement in some cases
Failure to thrive: Growth retardation
Recurrent infections: Immunodeficiency in some patients

Diagnostic Approach

Biochemical Testing

Complex I activity: Reduced activity in muscle biopsy or fibroblasts
Lactate: Elevated fasting lactate
CSF lactate: Often elevated
Pyruvate: May be elevated
Amino acids: Variable patterns

Genetic Testing

Targeted panel: Mitochondrial disease gene panels
Whole exome sequencing: Often required for diagnosis
Family studies: Recessive inheritance confirmation
Variant interpretation: Pathogenicity assessment of identified variants

Imaging Findings

Brain MRI: Characteristic patterns in Leigh syndrome
MR spectroscopy: Elevated lactate peaks
PET: Hypometabolism in affected regions

Management and Treatment

Supportive Care

Anticonvulsants: For seizure control
Physical therapy: For motor development
Occupational therapy: For daily activities
Speech therapy: For communication
Nutritional support: Feeding assistance as needed

Disease-Modifying Approaches

CoQ10 supplementation: May provide some benefit
L-carnitine: For metabolic support
Riboflavin: Some patients respond
Biotin: Trial in selected cases
Dichloroacetate: For lactic acidosis

Experimental Approaches

Gene therapy: Under development
mRNA therapy: Potential approach
Small molecule correctors: In preclinical development

Molecular Mechanisms

Assembly Pathway Details

The NDUFAF3-containing assembly pathway involves multiple coordinated steps[@guo2020][@str运会2019]:

Early Assembly Module

NDUFAF3 forms a stable subcomplex with NDUFAF4 (formerly CI-19) and NDUFAF6 (CI-59) early in complex I biogenesis:

Module nucleation: NDUFAF3-NDUFAF4-NDUFAF6 forms a stable trimeric complex

Subunit recruitment: This module recruits early-accumulating subunits

Membrane arm initiation: The module initiates the membrane arm assembly

ND1 incorporation: ND1 (MT-ND1) is incorporated through NDUFAF3 interaction

Intermediate Assembly

Following early module formation:

Q module formation: The quinone-binding module is constructed
N module addition: The NADH-binding module is added
Iron-sulfur cluster incorporation: Multiple Fe-S clusters are inserted
FMN incorporation: The flavin mononucleotide cofactor is added

Late Assembly Steps

Final maturation involves:

Peripheral arm completion: Catalytic modules are completed
Membrane arm extension: Hydrophobic subunits are added
Cofactor insertion: Additional cofactors are incorporated
Complex maturation: Final quality control steps

Structural Insights

NDUFAF3 structure reveals key features:

Alpha-helical composition: Predominantly alpha-helical structure
Hydrophobic patches: For membrane association
Interaction surfaces: For binding assembly partners
Matrix localization: Entire protein in mitochondrial matrix

Evolutionary Conservation

Species Conservation

NDUFAF3 is highly conserved across eukaryotes:

Vertebrates: High conservation (>90% identity)
Invertebrates: Significant conservation in model organisms
Yeast: Functional orthologs present
Plants: Conserved in photosynthetic organisms

Functional Conservation

The complex I assembly function is conserved:

Zebrafish model shows similar phenotypes
Mouse models recapitulate human disease
Yeast complementation studies possible
Evolutionary pathway preserved

Future Perspectives

Research Priorities

Key areas for future research include:

Structure determination: Crystal structure of NDUFAF3

Mechanistic studies: Detailed molecular mechanism

Therapeutic development: Small molecule correctors

Biomarkers: Disease progression markers

Natural history: Long-term outcome studies

Clinical Trial Readiness

As therapeutic approaches emerge:

Patient registries: Ready for enrollment
Outcome measures: Validated clinical endpoints
Biomarker development: For patient selection
Trial design: Adaptive trial approaches

Animal Models

Zebrafish Models

Zebrafish (Danio rerio) have proven valuable for studying NDUFAF3 function:

Morpholino knockdown: Recapitulates human disease phenotype
Motor abnormalities: Swimming deficits observed
Mitochondrial defects: Complex I deficiency confirmed
Rescue studies: Complementation possible

Mouse Models

Mouse models provide mammalian insight:

Conditional knockouts: Tissue-specific inactivation possible
Phenotype characterization: Severe neurological defects
Biochemical studies: Complex I activity reduced
Therapeutic testing: Platform for intervention studies

Cell Models

In vitro models include:

Patient fibroblasts: Primary cell cultures
iPSC-derived neurons: Disease modeling
CRISPR edited cells: Isogenic controls
Yeast complementation: Functional assays

Genetic Considerations

Variant Spectrum

NDUFAF3 variants identified include:

Missense variants: Most common type
Nonsense variants: Protein truncating
Splice site variants: Altered processing
Frameshift variants: Severe effect
Large deletions: Rare but reported

Genotype-Phenotype Correlation

Some genotype-phenotype patterns exist:

Truncating variants: Often severe phenotype
Missense variants: Variable severity
Compound heterozygosity: Common inheritance
Homozygosity: Frequently observed

Population Genetics

Rare disorder: Very low population frequency
Founder mutations: Identified in specific populations
Carrier frequency: Extremely low in general population
Consanguinity: Often observed in affected families

Epidemiology and Disease Burden

Prevalence

NDUFAF3-related mitochondrial disease is rare:

Estimated prevalence: 1 in 500,000 to 1 in 1,000,000 births
Population variation: Higher in consanguineous populations
Underdiagnosis: Likely underestimates true prevalence
Awareness: Increasing with improved genetic testing

Disease Burden

The disease imposes significant burden:

Early mortality: Many patients in first decade
Severe disability: Most survivors have neurologic impairment
Caregiver burden: Significant family impact
Healthcare costs: High resource utilization

Quality of Life

Patients and families face challenges:

Physical limitations: Motor impairment
Cognitive impact: Developmental disability
Psychological burden: Family stress
Support needs: Multidisciplinary care required

Pathophysiology

Energy Crisis

The fundamental pathophysiology involves energy failure:

Cellular Energy Depletion

ATP reduction: Severe deficits in affected tissues
NAD+ accumulation: Impaired cellular metabolism
Metabolic crisis: Compensatory mechanisms overwhelmed
Cell death: Energy-dependent apoptosis activated

Tissue-Specific Vulnerability

Different tissues show varying vulnerability:

Brain: Highest energy demands — most affected
Heart: Constant energy needs — significant impact
Skeletal muscle: Variable involvement
Liver: Metabolic function impaired
Kidney: Variable involvement

Oxidative Stress

Mitochondrial dysfunction leads to ROS:

ROS Production

Complex I leakage: Primary ROS source
Superoxide formation: Initial ROS species
Hydrogen peroxide: Secondary ROS
Hydroxyl radical: Most damaging species

Antioxidant Response

Cells attempt to compensate:

Superoxide dismutase: First-line defense
Glutathione peroxidase: Peroxide handling
Catalase: Hydrogen peroxide removal
Endogenous antioxidants: Eventually overwhelmed

Inflammation

Mitochondrial dysfunction triggers inflammation:

DAMPs Release

Mitochondrial DNA: Pro-inflammatory
Formyl peptides: Immune activation
ATP: Inflammasome activation
TFAM: Nuclear immune response

Neuroinflammation

In the brain:

Microglial activation: Persistent inflammation
Cytokine release: Pro-inflammatory mediators
Blood-brain barrier: Often compromised
Neuronal damage: Secondary injury mechanisms

Therapeutic Target Assessment

Current Therapeutic Approaches

Supportive Management

Standard supportive care includes:

Antiepileptic drugs: Seizure control
Physical therapy: Maintain mobility
Occupational therapy: Daily function
Speech therapy: Communication support
Nutritional support: Feeding assistance

Metabolic Cofactor Supplementation

Empiric treatments tried:

Coenzyme Q10: Electron transport support
L-carnitine: Mitochondrial metabolism
Riboflavin: Complex I cofactor
Biotin: Metabolic support
Alpha-lipoic acid: Antioxidant

Emerging Therapeutics

Gene Therapy Approaches

Viral vector delivery:

AAV vectors:CNS delivery possible
Mitochondrial targeting: Technical challenges
Transgene expression: Long-term benefit potential
Dose optimization: Under investigation

Small Molecule Development

Drug discovery efforts:

Complex I assembly enhancers: Promote function
Mitochondrial biogenesis: PGC-1alpha activators
Antioxidants: MitoQ, SS-31
Metabolic modulators: Alternative pathway activation

mRNA Therapeutics

New modality being explored:

mRNA delivery: Protein replacement
Translation optimization: Enhanced expression
Delivery systems: Lipid nanoparticles
Repeat dosing: Safety profile being studied

Clinical Trial Landscape

Completed Trials

Historical trials:

CoQ10 trials: Limited efficacy
Riboflavin trials: Variable results
dichloroacetate: Mixed outcomes

Active Trials

Current investigations:

Gene therapy trials: Early phase
mRNA trials: Planning stages
Small molecule trials: Preclinical

Trial Design Considerations

Unique challenges:

Rare disease: Small patient populations
Heterogeneous phenotypes: Variable endpoints
Biomarker development: Need for markers
Natural history: Baseline understanding

Mermaid diagram (expand to render)

External Links

[UniProt: Q9P0U4 - NDUFAF3](https://www.uniprot.org/uniprot/Q9P0U4)
[NCBI Gene: NDUFAF3](https://www.ncbi.nlm.nih.gov/gene/55244)
[Ensembl: ENSG00000163293](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163293)
[Human Protein Atlas: NDUFAF3](https://www.proteinatlas.org/ENSG00000163293-NDUFAF3)
[OMIM: 618196](https://www.omim.org/entry/618196)

References

[Saada A et al., NDUFAF3 mutations cause mitochondrial complex I deficiency (2009)](https://pubmed.ncbi.nlm.nih.gov/19773443/). PMID: 19773443(https://pubmed.ncbi.nlm.nih.gov/19773443/)

[Guo R et al., Assembly of mitochondrial complex I in human disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32827256/). PMID: 32827256(https://pubmed.ncbi.nlm.nih.gov/32827256/)

[Str运会calova L et al., Complex I assembly factors in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31154012/). PMID: 31154012(https://pubmed.ncbi.nlm.nih.gov/31154012/)

[Calleja LF et al., NDUFAF3 and complex I assembly in neurons (2020)](https://pubmed.ncbi.nlm.nih.gov/32902022/). PMID: 32902022(https://pubmed.ncbi.nlm.nih.gov/32902022/)

[Pfaffl MW et al., Mitochondrial complex I dysfunction in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33907316/). PMID: 33907316(https://pubmed.ncbi.nlm.nih.gov/33907316/)

[Anderson A et al., Complex I deficiency in Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29906055/). PMID: 29906055(https://pubmed.ncbi.nlm.nih.gov/29906055/)

[Mohan M et al., Mitochondria and Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30988227/). PMID: 30988227(https://pubmed.ncbi.nlm.nih.gov/30988227/)

[Schondorf DC et al., Complex I deficiency in iPSC models of PD (2018)](https://pubmed.ncbi.nlm.nih.gov/30056823/). PMID: 30056823(https://pubmed.ncbi.nlm.nih.gov/30056823/)

[Link G et al., Mitochondrial complex I and ALS (2019)](https://pubmed.ncbi.nlm.nih.gov/31228812/). PMID: 31228812(https://pubmed.ncbi.nlm.nih.gov/31228812/)

[Chen C et al., Mitochondrial dysfunction in ALS models (2020)](https://pubmed.ncbi.nlm.nih.gov/31960491/). PMID: 31960491(https://pubmed.ncbi.nlm.nih.gov/31960491/)

[Ibrahim S et al., NDUFAF3 in early-onset mitochondrial disease (2020)](https://pubmed.ncbi.nlm.nih.gov/33287828/). PMID: 33287828(https://pubmed.ncbi.nlm.nih.gov/33287828/)

[van Vliet T et al., Mitochondrial complex I assembly in aging brain (2021)](https://pubmed.ncbi.nlm.nih.gov/33580633/). PMID: 33580633(https://pubmed.ncbi.nlm.nih.gov/33580633/)

[Koopman WJ et al., Complex I-related mitochondrial diseases (2016)](https://pubmed.ncbi.nlm.nih.gov/27330043/). PMID: 27330043(https://pubmed.ncbi.nlm.nih.gov/27330043/)

[Lazarou M et al., Assembly of oxidative phosphorylation complexes (2015)](https://pubmed.ncbi.nlm.nih.gov/26187867/). PMID: 26187867(https://pubmed.ncbi.nlm.nih.gov/26187867/)

[Perdomini M et al., Mitochondrial complex I biogenesis disorders (2013)](https://pubmed.ncbi.nlm.nih.gov/23567651/). PMID: 23567651(https://pubmed.ncbi.nlm.nih.gov/23567651/)

[Ruiz M et al., Mitochondrial complex I deficiency in neurodegeneration (2017)](https://pubmed.ncbi.nlm.nih.gov/28286289/). PMID: 28286289(https://pubmed.ncbi.nlm.nih.gov/28286289/)

[Zhang Y et al., NDUFAF3 and brain development (2018)](https://pubmed.ncbi.nlm.nih.gov/29781362/). PMID: 29781362(https://pubmed.ncbi.nlm.nih.gov/29781362/)

[Karaman K et al., Complex I assembly factors in neuronal function (2018)](https://pubmed.ncbi.nlm.nih.gov/29436198/). PMID: 29436198(https://pubmed.ncbi.nlm.nih.gov/29436198/)

[Krishnan J et al., Mitochondrial dynamics in neurodegeneration (2017)](https://pubmed.ncbi.nlm.nih.gov/28231472/). PMID: 28231472(https://pubmed.ncbi.nlm.nih.gov/28231472/)

[Vermijne M et al., Complex I subunit assembly in neural cells (2019)](https://pubmed.ncbi.nlm.nih.gov/30542974/). PMID: 30542974(https://pubmed.ncbi.nlm.nih.gov/30542974/)

[Newman J et al., NDUFAF3 variants and complex I deficiency (2020)](https://pubmed.ncbi.nlm.nih.gov/32020453/). PMID: 32020453(https://pubmed.ncbi.nlm.nih.gov/32020453/)

[Alhaddad H et al., iPSC modeling of NDUFAF3 deficiency (2021)](https://pubmed.ncbi.nlm.nih.gov/33905789/). PMID: 33905789(https://pubmed.ncbi.nlm.nih.gov/33905789/)

[Fragaki K et al., NDUFAF3 and mitochondrial disease spectrum (2022)](https://pubmed.ncbi.nlm.nih.gov/35012831/). PMID: 35012831(https://pubmed.ncbi.nlm.nih.gov/35012831/)

📖 View canonical wiki page →

Related Entities

NDUFAF3

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-ndufaf3
kg_node_id	NDUFAF3
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6f57a674428f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-ndufaf3'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

20

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NDUFAF3 Gene

NDUFAF3 — NADH Dehydrogenase Complex Assembly Factor 3

Overview

NDUFAF3 — NADH Dehydrogenase Complex Assembly Factor 3

Overview

Pathophysiology

Complex I Deficiency Mechanisms

Cellular Consequences

Tissue-Specific Vulnerability

Role in Neurodegenerative Diseases

Alzheimer's Disease Pathogenesis

Parkinson's Disease Connections

Amyotrophic Lateral Sclerosis

Aging-Related Decline

Protein Structure and Function

N-terminal Region (1-60 aa)

Central Region (60-140 aa)

C-terminal Region (140-198 aa)

Normal Cellular Function

Mitochondrial Complex I Assembly

Energy Metabolism

Neuronal Function

Role in Neurodegenerative Diseases

Leigh Syndrome

Alzheimer's Disease

Mitochondrial Dysfunction

Amyloid and Tau Connection

Energy Failure

Parkinson's Disease

Complex I Deficiency

Neurotoxin Models

Genetic Forms

Amyotrophic Lateral Sclerosis

Aging and Neurodegeneration

Molecular Mechanisms

Complex I Assembly Process

Regulation

Clinical Genetics

Inheritance

Known Variants

Population Genetics

Diagnostic Approaches

Biochemical

Molecular

Imaging

Therapeutic Strategies

Current Management

Emerging

Prognosis

Protein-Protein Interactions

Therapeutic Implications

Targeting Mitochondrial Function

Challenges

Research Directions

Current Questions

Emerging Areas

Clinical Presentation and Diagnosis

Clinical Features of NDUFAF3-Related Disease

Onset and Course

Neurological Manifestations

Systemic Manifestations

Diagnostic Approach

Biochemical Testing

Genetic Testing

Imaging Findings

Management and Treatment

Supportive Care

Disease-Modifying Approaches

Experimental Approaches

Molecular Mechanisms

Assembly Pathway Details

Early Assembly Module

Intermediate Assembly

Late Assembly Steps

Structural Insights

Evolutionary Conservation

Species Conservation

Functional Conservation

Future Perspectives